IBDEI2EY ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40940,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,40940,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,40941,0)
 ;;=E74.39^^159^1996^35
 ;;^UTILITY(U,$J,358.3,40941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40941,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,40941,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,40941,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,40942,0)
 ;;=E83.30^^159^1996^46
 ;;^UTILITY(U,$J,358.3,40942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40942,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,40942,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,40942,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,40943,0)
 ;;=E83.51^^159^1996^28
 ;;^UTILITY(U,$J,358.3,40943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40943,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,40943,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,40943,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,40944,0)
 ;;=E83.52^^159^1996^26
 ;;^UTILITY(U,$J,358.3,40944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40944,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,40944,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,40944,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,40945,0)
 ;;=E87.5^^159^1996^27
 ;;^UTILITY(U,$J,358.3,40945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40945,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,40945,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,40945,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,40946,0)
 ;;=E89.2^^159^1996^48
 ;;^UTILITY(U,$J,358.3,40946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40946,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,40946,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,40946,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,40947,0)
 ;;=E89.6^^159^1996^47
 ;;^UTILITY(U,$J,358.3,40947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40947,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,40947,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,40947,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,40948,0)
 ;;=L68.0^^159^1996^25
 ;;^UTILITY(U,$J,358.3,40948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40948,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,40948,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,40948,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,40949,0)
 ;;=M80.00XA^^159^1996^2
 ;;^UTILITY(U,$J,358.3,40949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40949,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,40949,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,40949,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,40950,0)
 ;;=M81.0^^159^1996^3
 ;;^UTILITY(U,$J,358.3,40950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40950,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,40950,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,40950,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,40951,0)
 ;;=M85.80^^159^1996^44
 ;;^UTILITY(U,$J,358.3,40951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40951,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,40951,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,40951,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,40952,0)
 ;;=N62.^^159^1996^24
 ;;^UTILITY(U,$J,358.3,40952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40952,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,40952,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,40952,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,40953,0)
 ;;=E10.43^^159^1996^6
 ;;^UTILITY(U,$J,358.3,40953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40953,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,40953,1,4,0)
 ;;=4^E10.43
